Elza C. de Bruin

4.2k total citations · 1 hit paper
23 papers, 1.4k citations indexed

About

Elza C. de Bruin is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Elza C. de Bruin has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elza C. de Bruin's work include Cancer Genomics and Diagnostics (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Elza C. de Bruin is often cited by papers focused on Cancer Genomics and Diagnostics (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Elza C. de Bruin collaborates with scholars based in United Kingdom, United States and Netherlands. Elza C. de Bruin's co-authors include Jan Paul Medema, Charles Swanton, Nicholas McGranahan, Nicolai J. Birkbak, Zoltán Szállási, Francesco Favero, Crispin T. Hiley, Lucy T.C. Peltenburg, Julian Downward and Corrie A.M. Marijnen and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Elza C. de Bruin

22 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

2015 432 citations Nicholas McGranahan, Francesco Favero et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elza C. de Bruin United Kingdom	12	662	628	567	402	208	23	1.4k
Amy E. McCart Reed Australia	22	707 1.1×	534 0.9×	685 1.2×	359 0.9×	226 1.1×	66	1.5k
Marta Castiglia Italy	22	730 1.1×	608 1.0×	619 1.1×	518 1.3×	134 0.6×	52	1.5k
Arran Turnbull United Kingdom	23	602 0.9×	590 0.9×	533 0.9×	266 0.7×	142 0.7×	57	1.4k
Mariangela Russo Italy	14	668 1.0×	308 0.5×	488 0.9×	265 0.7×	239 1.1×	26	1.2k
Pradip De United States	22	1.0k 1.6×	596 0.9×	988 1.7×	438 1.1×	220 1.1×	36	2.0k
Hui Yao China	19	925 1.4×	964 1.5×	365 0.6×	351 0.9×	115 0.6×	32	1.6k
Naoise C. Synnott Ireland	13	793 1.2×	370 0.6×	706 1.2×	235 0.6×	169 0.8×	26	1.4k
Ximing Xu China	24	896 1.4×	599 1.0×	527 0.9×	324 0.8×	131 0.6×	101	1.6k
Julie A. Vendrell France	21	905 1.4×	538 0.9×	563 1.0×	308 0.8×	126 0.6×	55	1.5k
Simonetta Buglioni Italy	22	930 1.4×	511 0.8×	772 1.4×	227 0.6×	173 0.8×	71	1.7k

Countries citing papers authored by Elza C. de Bruin

Since Specialization

Citations

This map shows the geographic impact of Elza C. de Bruin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elza C. de Bruin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elza C. de Bruin more than expected).

Fields of papers citing papers by Elza C. de Bruin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elza C. de Bruin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elza C. de Bruin. The network helps show where Elza C. de Bruin may publish in the future.

Co-authorship network of co-authors of Elza C. de Bruin

This figure shows the co-authorship network connecting the top 25 collaborators of Elza C. de Bruin. A scholar is included among the top collaborators of Elza C. de Bruin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elza C. de Bruin. Elza C. de Bruin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wigmore, Eleanor M., Stuart C. Williamson, Amanda L. Christie, et al.. (2025). The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer. npj Breast Cancer. 11(1). 36–36.

Hamilton, Erika, Gerald S. Falchook, Judy S. Wang, et al.. (2024). Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Targeted Oncology. 19(6). 879–892. 3 indexed citations

Sobsey, Constance A., Robert Popp, René P. Zahedi, et al.. (2024). mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA -Altered Tumors. Cancer Research Communications. 4(8). 2058–2074. 2 indexed citations

Eberlein, Cath, Stuart C. Williamson, Susana R�os, et al.. (2024). Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British Journal of Cancer. 130(8). 1377–1387. 11 indexed citations

Garrido-Castro, Ana C., Jorge Gómez Tejeda Zañudo, José‐Tomás Navarro, et al.. (2023). 475P Dynamics of TROP2 expression in triple-negative breast cancer. Annals of Oncology. 34. S380–S381. 1 indexed citations

Lipsyc-Sharf, Marla, Elza C. de Bruin, Robert McEwen, et al.. (2022). Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Clinical Oncology. 40(22). 2408–2419. 85 indexed citations

Vaclová, Tereza, Atanu Chakraborty, James Sherwood, et al.. (2022). Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Scientific Reports. 12(1). 2699–2699. 8 indexed citations

Vaclová, Tereza, Ursula Grazini, Lewis S. C. Ward, et al.. (2021). Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nature Communications. 12(1). 1780–1780. 46 indexed citations

Bruin, Elza C. de, Claire Corcoran, Jayne C. Fox, et al.. (2017). Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients. PLoS ONE. 12(5). e0175779–e0175779. 9 indexed citations

10.

McGranahan, Nicholas, Francesco Favero, Elza C. de Bruin, et al.. (2015). Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Science Translational Medicine. 7(283). 283ra54–283ra54. 432 indexed citations breakdown →

11.

Bruin, Elza C. de, Nicholas McGranahan, & Charles Swanton. (2015). Analysis of intratumor heterogeneity unravels lung cancer evolution. Molecular & Cellular Oncology. 2(3). e985549–e985549. 17 indexed citations

12.

Bruin, Elza C. de, Catherine Cowell, Patricia H. Warne, et al.. (2014). Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer. Cancer Discovery. 4(5). 606–619. 154 indexed citations

13.

Hiley, Crispin T., Elza C. de Bruin, Nicholas McGranahan, & Charles Swanton. (2014). Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome biology. 15(8). 453–453. 163 indexed citations

14.

Bruin, Elza C. de, Tiffany Taylor, & Charles Swanton. (2013). Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Medicine. 5(11). 101–101. 34 indexed citations

15.

Bruin, Elza C. de & Jan Paul Medema. (2008). Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treatment Reviews. 34(8). 737–749. 226 indexed citations

16.

Bruin, Elza C. de, Simone van de Pas, Cornelis J.�H. van de Velde, et al.. (2007). Gene expression profiling reveals two separate mechanisms regulating apoptosis in rectal carcinomas in vivo. APOPTOSIS. 12(9). 1671–1680. 2 indexed citations

17.

Bruin, Elza C. de, Simone van de Pas, Esther H. Lips, et al.. (2005). Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles. BMC Genomics. 6(1). 142–142. 42 indexed citations

18.

Peltenburg, Lucy T.C., et al.. (2004). c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers. Melanoma Research. 14(1). 3–12. 8 indexed citations

19.

Bruin, Elza C. de, et al.. (2003). A serine protease is involved in the initiation of DNA damage-induced apoptosis. Cell Death and Differentiation. 10(10). 1204–1212. 50 indexed citations

20.

Goodman, Richard B., Elza C. de Bruin, Randine L. Dowling, et al.. (1993). IL‐1 and its role in rat carrageenan pleurisy. Mediators of Inflammation. 2(1). 33–39. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact